From Financial Modeling Prep: 2025-05-30 18:00:00

Innovative biotech company Lantern Pharma (NASDAQ:LTRN) focuses on precision oncology therapies using AI and machine learning. Their drug LP-184 shows promise in treating rare pediatric cancer ATRT, highlighted at the SNO Pediatric Conference. Despite a 4.27% stock decrease to $3.00, Lantern Pharma’s market cap is $32.3 million, with key shareholder Kreis Leslie W. selling shares.



Read more at Financial Modeling Prep:: Lantern Pharma Inc. (NASDAQ:LTRN) Focuses on Preci…